Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CHMP’s January Recommendations Include Tofacitinib And Biosimilar Adalimumab

Executive Summary

The European Medicines Agency’s Committee for Medicinal Products for Human Use notes also that Sandoz withdrew its application for the biosimilar Zioxtenzo (pegfilgrastim).

Advertisement

Related Content

New Treatments For Psoriasis, Ovarian Cancer And MS Seeking CHMP Thumbs Up This Week
New FDA Revlimid Approval Extends Celgene's Myeloma Empire
Amgen’s Biosimilar Adalimumab First To EU Nod But No Launch
Pfizer's Xeljanz Set To Lag Lilly's Olumiant In Europe Following Past Rebuffs
Sandoz Sanguine On Market Opportunity Despite Biosimilar Neulasta Setback

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel